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patients with visit 2 data available for ITT analysis (152 patients
enrolled) were included (mean age 48 years, 51% female, mean
BMI 27 kg/m2, 75% sedentary lifestyle). Upon inclusion, 21%
had never received any treatment, 44% were receiving, or had
received antacids, 21% H2-receptor blockers, 46% had received
PPI therapy proton pump inhibitors (PPI) therapy (34% omepra-
zole, 31 esomeprazole, 21% pantoprazole, 11% rabeprazole,
3% lansoprazole). After visit 1 physicians changed treatment in
favor of full-dose PPIs (94% of cases), mainly esomeprazole
(75%) and stopped almost all h2-receptors blockers (1%).
Seventy-ﬁve percent of patients were in acute phase treatment
after visit 1 which changed to maintenance treatment phase in
91% of patients after visit 3. There was a concomitant dose
reduction of 40 mg to 20 mg for the most prescribed PPI esome-
prazole. Forty-percent of patients became The prescribed dose
was changed to a median of 20 mg at visit 2 in 32% of patients.
The severity of GERD symptoms decreased substantially
throughout the study with 84% of patients having moderate or
severe GERD in visit 1, 23% in visit 2 and 11% in visit 3.
Concurrently, the GIS scores decreased signiﬁcantly (-1.27 for
upper GI symptoms, -0.92 for other related GI symptoms and
-0.85 for the impact on life; p < 0.001). The GIS was judged to
be helpful for approximately 80% of the patients by the physi-
cians. At all visits, the GIS mean-scores increased markedly with
increasing severity of disease (clinical judgment). The correlation
between GIS mean-scores and endoscopy ﬁndings or the physi-
cian’s judgment of the usefulness of the GIS was less pronounced.
CONCLUSIONS: GIS scores improved with GERD PPI treat-
ment and were judged helpful by the physician. GIS may thus
have an added value over these assessments in determining the
appropriate treatment and evaluating the patient’s response to
this treatment.
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OBJECTIVES: In some European Union countries in recent years
the use of proton pump inhibitors (PPIs) has greatly increased. In
march 2006 in Italy lansoprazole came off patent and became a
relatively cheap treatment. Several national and regional mea-
sures to rationalise PPIs spending growth were taken to promote
the choice of less expensive PPI, lansoprazole, regardless of his
antisecretory potency. The goal of this study was to compare
general practitioners’prescription (GPs) of different PPIs and
explore how GPs PPI prescribing changes following the loss of
lansoprazole patent. METHODS: We extracted all records of PPI
prescribing within a General Practitioner Research Database of
99 GPs located in Naples, Italy, and analysed them using
Microsoft SQL Server 2005. All records for patients who had
been prescribed a PPI were divided into calendar years from 2005
to 2007 (the year prior to and following lansoprazole generic).
PPI consumption were quantiﬁed using Deﬁned Daily Dose
system (DDD). RESULTS: The total volume of PPI’s prescribing
increased steadily over the 3 years. The proportion of deﬁned
daily doses accounted for by lansoprazole was 11.8% in 2005
rising to 35.9% in 2007. The contribution of omeprazole, the
most often PPI prescribed, to total PPIs prescriptions decreased
from 43.0% to 22.7% in the same period, while esomeprazole
contribution remained costant. Following the loss of patent, new
lansoprazole prescriptions increased substantially; 32.7% of sub-
jects switched from another PPI to lansoprazole. CONCLU-
SIONS: To reduce costs GPs have been coming under pressure
encouraging the prescription of a cheaper drug. The wide varia-
tion in PPI prescribing suggests that the choice of PPI by GPs was
distorted by the effect of lansoprazole “liberalization”.
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OBJECTIVES: Pathologic deterioration of intervertebral discs,
characterized by annular tears, can cause severe, unremitting low
back pain [LBP] resulting in loss of function and quality of life
for millions of individuals worldwide. Patients experiencing
severe back symptoms beyond six months have poor prognosis
for recovery with conservative management alone. Open surgical
intervention such as spinal fusion and artiﬁcial disc replacement
are being utilized with escalating frequency, however costs and
risks are high. Performed in the outpatient setting, intradiscal
electrothermal therapy [IDET] is minimally invasive, less costly
alternative to surgery for patients nonresponsive to conservative
care. This study prospectively evaluated effectiveness of IDET in
50 consecutive adult patients refractory to conservative care of at
least six months duration. METHODS: Using MRI and dis-
cography to establish internal disc disruption, 50 patients with
lumbar discogenic pain were identiﬁed, underwent IDET treat-
ment and followed for 24 months. Back pain severity (11-point
numeric scale) and back function (Oswestry disability index
[ODI]) were evaluated pre-treatment, 12 and 24 months post-
procedure. Clinical success deﬁned as lack of follow-up surgery,
2-point pain, and 15-point ODI improvement. RESULTS:
Average 68% and 66% improvements in pain and ODI, respec-
tively, between pre-treatment and 24 months (p < 0.0001 for
both comparisons). Global clinical success rate was 78% (39/50).
No complications occurred during IDET procedure. No post-
procedural adverse events such as infections or neurological
sequelae reported. CONCLUSIONS: The signiﬁcant and robust
clinical improvements in function through 24 months and 78%
global success rate achieved in this study compare favorably with
previously published results for IDET using similar patient
selection criteria. Careful patient selection based on discography
and imaging may improve outcomes. Risk of procedure-related
adverse events is low. IDET offers a safe, low-cost treatment
alternative with demonstrated durable, long-term clinical
beneﬁts in the continuum of care of patients with discogenic
LBP.
HEALTH CARE INTERVENTIONS—Cost Studies
PHC2
IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL
SURGERY ON HOSPITAL BUDGET
Krysanov I, Kulikov A,Yagudina RI
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: To assess the effectiveness and economic conse-
quences for Moscow hospitals of the “ready-to-use” collagen
patch coated with thrombin and ﬁbrinogen—trade name
TachoComb—compared with current haemostatic practice in
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